Literature DB >> 22971465

Arterial, venous and other vascular risk factors in multiple sclerosis.

Yuval Karmon1, Murali Ramanathan, Alireza Minagar, Robert Zivadinov, Bianca Weinstock-Guttman.   

Abstract

PURPOSE OF REVIEW: This article reviews vascular risk factors with specific emphasis on lipid abnormalities reported to be associated with multiple sclerosis (MS). RECENT
FINDINGS: The current paradigm of MS, supported only partially by MS lesion histopathology and its animal model (experimental allergic encephalomyelitis) considers MS to be a predominantly autoimmune disease. Until recently, most of the known risk factors for MS were interpreted in the context of the autoimmune theory, which still fails to explain why genetically close populations exposed to similar pathogens and/or environmental risk factors have different incidences of MS. Therapies which partially modulate the inflammatory arm of MS pathogenesis, fail to achieve similar benefits in later disease stages, when less inflammatory lesions and more neurodegeneration are present. Several studies have reported an increased cardiovascular morbidity in MS patients and that vascular comorbidity at any time during the disease course also increased the risk of progressive disability. A condition named chronic cerebrospinal venous insufficiency provided a different perspective, on the possible association of MS with the abnormalities of the venous system. Our recent findings revealed increased prevalence of chronic cerebrospinal venous insufficiency associated with MS disease progression as well as with other neurologic disorders. On the other hand, recently emerging evidence indicates that there is an association between lipoproteins and cholesterol metabolism and MS disease progression. Expanded disability status scale worsening was associated with higher baseline low-density lipoprotein and total cholesterol, and higher serum high-density lipoprotein levels were associated with lower contrast-enhancing T1-weigthed lesion volume. It is thought that apolipoprotein A-1 and paraoxonase anti-oxidant enzyme are associated with high-density lipoprotein and contribute to its anti-oxidant and anti-inflammatory properties. A significant inter-dependence was also recently demonstrated between vitamin D, one of the best known environmental risk factors for MS and MS disease progression and the serum lipid profile. Future work in this direction is required in order to better elucidate the role of lipid metabolism and vascular pathology in pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22971465     DOI: 10.1179/1743132812Y.0000000077

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  12 in total

Review 1.  Dietary Interventions and Multiple Sclerosis.

Authors:  Ghadah Altowaijri; Allison Fryman; Vijayshree Yadav
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

2.  Increased sensitivity of Apolipoprotein E knockout mice to swainsonine dependent immunomodulation.

Authors:  David W Scott; Leland L Black; Matthew O Vallejo; Janusz H Kabarowski; Rakesh P Patel
Journal:  Immunobiology       Date:  2014-03-02       Impact factor: 3.144

Review 3.  Correlation of geographic distributions of haptoglobin alleles with prevalence of multiple sclerosis (MS) - a narrative literature review.

Authors:  Vladimir V Bamm; Arielle M Geist; George Harauz
Journal:  Metab Brain Dis       Date:  2016-11-02       Impact factor: 3.584

4.  Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature.

Authors:  Ganta Vijay Chaitanya; Seiichi Omura; Fumitaka Sato; Nicholas E Martinez; Alireza Minagar; Murali Ramanathan; Bianca Weinstock Guttman; Robert Zivadinov; Ikuo Tsunoda; Jonathan S Alexander
Journal:  J Neuroinflammation       Date:  2013-10-14       Impact factor: 8.322

5.  Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis.

Authors:  Giovanna Marchetti; Nicole Ziliotto; Silvia Meneghetti; Marcello Baroni; Barbara Lunghi; Erica Menegatti; Massimo Pedriali; Fabrizio Salvi; Ilaria Bartolomei; Sofia Straudi; Fabio Manfredini; Rebecca Voltan; Nino Basaglia; Francesco Mascoli; Paolo Zamboni; Francesco Bernardi
Journal:  Mol Med       Date:  2018-08-09       Impact factor: 6.354

6.  Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?

Authors:  Jagannadha Avasarala; Naveen Parti
Journal:  Front Neurol       Date:  2018-08-08       Impact factor: 4.003

7.  Neuroinflammation as the proximate cause of signature pathogenic pattern progression in amyotrophic lateral sclerosis, AIDS, and multiple sclerosis.

Authors:  Lawrence M Agius
Journal:  Patholog Res Int       Date:  2012-12-04

8.  Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients.

Authors:  Elliot Graziano; Jesper Hagemeier; Bianca Weinstock-Guttman; Deepa P Ramasamy; Robert Zivadinov
Journal:  Neuroimage Clin       Date:  2015-08-01       Impact factor: 4.881

Review 9.  Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare.

Authors:  Uwe Gröber; Jörg Spitz; Jörg Reichrath; Klaus Kisters; Michael F Holick
Journal:  Dermatoendocrinol       Date:  2013-11-05

Review 10.  Venous endothelial injury in central nervous system diseases.

Authors:  Jonathan S Alexander; Leonard Prouty; Ikuo Tsunoda; Chaitanya Vijay Ganta; Alireza Minagar
Journal:  BMC Med       Date:  2013-10-11       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.